
    
      This open-label, phase 1b/2 dose-escalation and dose-expansion study is designed to evaluate
      the safety and maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D) of RMC-4630
      in combination with cobimetinib in participants with relapsed/refractory solid tumors; and of
      RMC-4630 in combination with osimertinib in adult participants with EGFR mutation-positive
      locally advanced or metastatic NSCLC.
    
  